DCK Antibody
-
中文名稱：DCK兔多克隆抗體
-
貨號：CSB-PA006547GA01HU
-
規格：￥3,900
-
其他：
產品詳情
-
Uniprot No.：
-
基因名：DCK
-
別名：dCK antibody; DCK protein antibody; DCK_HUMAN antibody; Deoxycytidine kinase antibody; Deoxynucleoside kinase antibody; EC 2.7.1 antibody; EC 2.7.1.74 antibody; MGC117410 antibody; MGC138632 antibody; OTTHUMP00000219118 antibody; OTTHUMP00000219119 antibody
-
宿主：Rabbit
-
反應種屬：Human,Mouse,Rat
-
免疫原：Human DCK
-
免疫原種屬：Homo sapiens (Human)
-
抗體亞型：IgG
-
純化方式：Antigen Affinity purified
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
-
產品提供形式：Liquid
-
應用范圍：ELISA,WB
-
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
相關產品
靶點詳情
-
功能：Phosphorylates the deoxyribonucleosides deoxycytidine, deoxyguanosine and deoxyadenosine. Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents.
-
基因功能參考文獻：
- study suggests that DCK knockdown facilitates apoptosis while inhibiting proliferation and tumorigenicity in vivo of cervical cancer HeLa cells. PMID: 28820179
- Phosphorylated and activated DCK can inhibit radiation-induced cell death including apoptosis and mitotic catastrophe, and promote radiation-induced autophagy through PI3K/Akt/mTOR pathway. PMID: 27879648
- Low deoxycytidine kinase expression is associated with periampullary adenocarcinoma. PMID: 26362587
- expression and A9846G AA genotype significantly associated with reduced mortality in pancreatic ductal adenocarcinoma PMID: 26962792
- recently described a human deoxycytidine kinase mutant (G12) that sensitizes cancer cell lines to treatment with gemcitabine. Here, starting from the G12 variant, we identified a mutant that triggers even greater sensitisation to gemcitabine than G12. PMID: 26485161
- RNA expression of deoxycytidine kinase (DCK), human equilibrative nucleoside transporter-1 (ENT1) and ribonucleotide reductase M1 (RRM1) were significantly higher and cytidine deaminase (CDA) was significantly lower in ex vivo Ara-C sensitive samples. PMID: 26083014
- n the multivariate Cox regression analysis, we found that age at diagnosis, wild-type genotype of the CDA A79C polymorphism, and wild-type genotype of the dCK C360G polymorphism were the most significant prognostic factors for predicting the risk of death PMID: 26090398
- results strongly suggest that (1) the E197K alteration in DCK causes inactivation of DCK, and that (2) loss of the normal E197 allele is the crucial mechanism in acquisition of gemcitabine resistance in the RMKN28 tumor cell line PMID: 26196746
- DCK rs12648166 and DCK rs4694362 SNPs were associated with hematologic toxicity (OR = 2.63, CI 95% = 1.37-5.04, P = 0.0036 and OR = 2.53, CI 95% = 1.34-4.80, P = 0.0044, respectively). PMID: 25557962
- These findings indicate that the decitabine metabolic pathway affects its therapeutic effects, lower hENT1 expression may induce primary resistance and down-regulated DCK expression may be related to secondary resistance. PMID: 25533931
- induction after hypoxia plays a role in the progression of pulmonary fibrosis by contributing to alveolar epithelial cell proliferation PMID: 25358054
- DCK expression levels are prognostic and had predictive value for sensitivity to 5-FU in pancreatic cancer. PMID: 24618665
- DCK could regulate the migration and invasion of fibroblast-like synoviocytes through AKT pathway in rheumatoid arthritis patients. PMID: 24294360
- PP2A constitutively dephosphorylates dCK in cells and negatively regulates its activity. PMID: 24462681
- Report genetic variation in deoxycytidine kinase and subsequent gemcitabine metabolism. PMID: 23230131
- It is evident that the DCK and CDA polymorphisms might be the important markers for the AML patients' therapy outcomes in a Chinese population. PMID: 22884143
- Hematologic toxicity such as neutropenia, thrombocytopenia, and anemia were not associated with three tagged single-nucleotide polymorphisms of deoxycytidine kinase or haplotypes. Genetic variations did not affect survival of the patients. PMID: 23035362
- High levels of dCK in pancreatic ductal adenocarcinoma predict longer survival times in patients treated with adjuvant gemcitabine. PMID: 22705007
- These results indicate that the inactivation of DCK is one of the crucial mechanisms in acquisition of gemcitabine resistance. PMID: 22490663
- Although dFdU increased the net intracellular radioactivity of [5-(3)H]dFdC at 24 h in control cells, this increase was abolished in the absence of dCK activity. PMID: 21832002
- Data show that the CDA/DCK ratio was 3 fold higher in non-responders than responders (P<.05), suggesting that this could be a mechanism of primary resistance. PMID: 21858090
- dCK expression level in fludarabine-sensitive patients was much higher than in Flud-resistant patients. PMID: 20137114
- High deoxycytidine kinase is associated with response to pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer. PMID: 21336182
- Data show that dCK must make the transition between the open and closed states during the catalytic cycle. PMID: 21351740
- Overexpressed dCK and knocked down p8 is associated with enhancement of gemcitabine sensitivity in pancreatic cancer. PMID: 21225236
- Data indicate that variant C28624T showed a lower risk of lymphopenia (P=0.04), but a higher risk of neutropenia. PMID: 21030078
- We show that ABCG2 influence on clofarabine cytotoxicity was markedly influenced by dCK activity PMID: 21245102
- Data show that dCK-360G allele was found to increase the risk of mucositis after exposure to low-dose cytarabine in childhood ALL therapy. PMID: 20890066
- Site-directed mutagenesis demonstrated that only Ser-74 phosphorylation was involved in dCK activation by casein kinase 1 delta, strengthening the key role of this residue in the control of dCK activity. PMID: 20637175
- Data show that phosphorylation of the three other sites, located in the N-terminal extremity of the protein, does not significantly modify dCK activity, but phosphorylation of Thr-3 could promote dCK stability. PMID: 20544527
- Data show that methylation was detected in one of the SP1 binding sites of the dCK promoter, in most tested cancer cell lines and in patient samples from brain tumors and leukemia. Methylation might therefore regulate transcription of dCK. PMID: 20544528
- it is residue Asp133 of dCK that is most responsible for discriminating against the thymine base PMID: 20614893
- Sensitivity of two pancreatic cancer cell lines transduced with deoxycytidine kinase to gemcitabine elevated dramatically in comparison with control cells. PMID: 20043109
- alternatively spliced dCK forms found in acute myeloid leukemia cells play an important role in cytarabine resistance PMID: 11830489
- Molecular basis of 2',3'-dideoxycytidine-induced drug resistance in human cells. PMID: 11952160
- Data show that inorganic tripolyphosphate (PPP(i)) is a good donor for human ceoxycytidine kinase and deoxyguanosine kinase. PMID: 12535661
- human deoxycytidine kinase promoter activity is regulated by USF and Sp1 PMID: 14514691
- dCK can act as a phosphorylase, similar to the nucleoside phosphorylase family of enzymes PMID: 15561147
- analysis of antitumor drug binding to deoxycytidine kinase PMID: 15571255
- dCK expression varies between individual samples and between different types of malignancies and may play a role in resistance to ara-C in particular tumor types PMID: 15571257
- deoxycytidine kinase activity is stimulated by 2-chlorodeoxyadenosine and aphidicolin in the cellular context PMID: 15571258
- deoxycytidine kinase activity is regulated by reversible phosphorylation PMID: 15571259
- an increased expression of mRNA, specific for thymidine kinase 1, dCK and thymidine phosphorylase, may be involved in carcinogenic processes in the human thyroid PMID: 15978330
- dCK activity can be controlled by phosphorylation in intact cells, and Ser-74 is required for activity PMID: 16361699
- Crystal structures of a deoxycytidine kinase variant lacking a flexible insert (residues 65-79) reveal major changes in the donor base binding loop (residues 240-247) between UDP-bound and ADP-bound forms, involving significant main-chain rearrangement. PMID: 16401075
- an increase in activity of dCK, TK1 and 2 might be involved in an adaptive response of cultured human squamous lung carcinoma cells to radiation by facilitation of DNA repair PMID: 16969512
- deoxycytidine kinase has a role in lymphoma cell sensitivity to cladribine PMID: 17065053
- analysis of phosphorylation sites on human deoxycytidine kinase PMID: 17065079
- analysis of deoxycytidine kinase reversible phosphorylation in normal human lymphocytes PMID: 17065080
- deoxycytidine kinase activity is enhanced after pulsed low dose rate and single dose gamma irradiation PMID: 17065085
顯示更多
收起更多
-
亞細胞定位：Nucleus.
-
蛋白家族：DCK/DGK family
-
數據庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
